English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Mapping the MHC class I spliced immunopeptidome of cancer cells.

MPS-Authors
/persons/resource/persons208298

Liepe,  J.
Research Group of Quantitative and System Biology, MPI for Biophysical Chemistry, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Liepe, J., Sidney, J., Lorenz, F. K. M., Sette, A., & Mishto, M. (2019). Mapping the MHC class I spliced immunopeptidome of cancer cells. Cancer Immunology Research, 7(1), 62-76. doi:10.1158/2326-6066.CIR-18-0424.


Cite as: http://hdl.handle.net/21.11116/0000-0002-7DFD-6
Abstract
Anti-cancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines. The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer.